Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC) was the target of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 2,870,000 shares, a drop of 7.1% from the November 15th total of 3,090,000 shares. Based on an average trading volume of 263,800 shares, the short-interest ratio is presently 10.9 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CELC. Samlyn Capital LLC grew its stake in shares of Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock worth $21,735,000 after purchasing an additional 637,190 shares during the period. Driehaus Capital Management LLC grew its position in Celcuity by 62.3% during the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock worth $3,351,000 after buying an additional 78,525 shares during the period. Blue Owl Capital Holdings LP purchased a new position in Celcuity in the second quarter valued at about $1,065,000. BNP Paribas Financial Markets lifted its position in shares of Celcuity by 2,083.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock valued at $673,000 after acquiring an additional 43,044 shares during the period. Finally, Braidwell LP boosted its stake in shares of Celcuity by 71.2% during the 3rd quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after acquiring an additional 367,663 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

NASDAQ CELC traded up $0.04 on Tuesday, hitting $12.59. 33,831 shares of the company’s stock were exchanged, compared to its average volume of 276,164. The firm has a market cap of $467.47 million, a price-to-earnings ratio of -4.76 and a beta of 0.74. The firm’s 50-day moving average price is $14.29 and its two-hundred day moving average price is $15.47. Celcuity has a fifty-two week low of $11.51 and a fifty-two week high of $22.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Analyst Ratings Changes

A number of brokerages recently weighed in on CELC. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Celcuity in a research note on Friday, November 15th. Lifesci Capital assumed coverage on Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Finally, Stifel Nicolaus increased their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $29.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.